CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Pre-Tax Margin

Income before tax as a percentage of revenue.

CRISPR Therapeutics AGNASDAQ: CRSP

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin widens to -879.0%

Pre-tax margin was -879.0% in Q3 FY2026, up 11024.5 pp from a year earlier. On a trailing-twelve-month basis it was -1802.2%, down 515.0 pp year over year. Over 3 fiscal years it widened by 132731.0 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-879.0%+6.9 pp QoQ
Last fiscal yearDec 2025
-16466.2%-15430.1 pp YoY
LTMSep 2026
-1802.2%-515.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+11024.5 pp——
1 year-15430.1 pp——
3 years+132731.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-16466.2%
Year-over-year change
-15430.1pp

Pre-Tax Margin vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 pre-tax margin of -1802.2% is the lowest of the 7 companies compared; the peer median is -246.5%.
  • Its year-over-year change of -515.0 pp is the lowest of 7, against a peer median of +203.5 pp.
  • Over three fiscal years its change of +132731.0 pp compares with a peer median of +279.9 pp.
CRSP Competitors Peer median
Pre-Tax Margin for CRSP and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+411.7 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+154.5 pp
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-211.5% -12.5 pp+259.8 pp
EDITEditas Medicine, Inc.LTM Mar 2026-281.6% +419.5 pp+723.2 pp
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+135.0 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-597.0% +557.1 pp+299.9 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1802.2% -515.0 pp+132731.0 pp
Peer median (excluding CRSP) -246.5%+203.5 pp+279.9 pp

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue913.08M436K370M35M3.51M
Cost of Revenue101.18M110.25M130.25M110.25M232.96M
Gross Profit811.9M(109.81M)239.75M(75.25M)(229.45M)
Gross Margin88.9%-25186.7%64.8%-215.0%-6537.0%
Research & Development340.57M461.65M387.33M320.65M265.33M
Selling, General & Admin99.69M102.46M76.16M72.98M73.54M
Operating Expenses438.38M563.35M462.29M391.32M338.87M
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
EBITDA397.48M(626.33M)(130.89M)(343.41M)(558.49M)
EBITDA Margin43.5%-143653.2%-35.4%-981.2%-15911.3%
Operating Income373.53M(673.16M)(222.54M)(466.57M)(568.32M)
Operating Margin40.9%-154394.7%-60.1%-1333.0%-16191.4%
Interest Income00000
Interest Expense00000
Other Income / Expenses6M22.66M71.82M103.9M(9.65M)
Income Before Tax379.53M(650.5M)(150.72M)(362.67M)(577.97M)
Pre-Tax Margin41.6%-149197.2%-40.7%-1036.2%-16466.2%
Income Tax Expense1.87M(325K)2.89M3.59M3.63M
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Net Margin41.4%-149122.7%-41.5%-1046.4%-16569.8%
EPS (Basic)4.97(8.36)(1.94)(4.34)(6.47)
EPS (Diluted)4.70(8.36)(1.94)(4.34)(6.47)
Weighted Avg Shares75.95M77.75M79.22M84.36M89.93M
Weighted Avg Shares (Diluted)80.39M77.75M79.22M84.36M89.93M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.